Loading...
Rising siRNA Manufacturing Risks May Delay Profitability Yet Long-Term Upside Remains
AN
AnalystLowTarget
Not Invested
Community Contributor
Published
12 Dec 25
Views
37
12 Dec
US$2.75
AnalystLowTarget's Fair Value
US$2.00
37.5% overvalued intrinsic discount1Y
17.0%7D
8.7%1Y
17.0%7D
8.7%You can edit this narrative until Dec 13 12:10 AM. Then, changes will post as Updates.
Author's Valuation
US$237.5% overvalued intrinsic discount
AnalystLowTarget Fair Value